Skip to main content
Acta Crystallographica Section E: Crystallographic Communications logoLink to Acta Crystallographica Section E: Crystallographic Communications
. 2025 Dec 14;81(Pt 12):1149–1152. doi: 10.1107/S2056989025010047

Crystal structure and Hirshfeld surface analysis of anhydrous salt of levofloxacin and 4-methyl­benzoic acid

Bhumi C Patel a, Krunal M Modi a, J Prakasha Reddy a,b,*
Editor: F F Ferreirac
PMCID: PMC12810259  PMID: 41551402

In the crystal of the anhydrous salt of levofloxacin with 4-methyl­benzoic acid, C18H21FN3O4+·C8H7O2, the levofloxacinium ions inter­act with the 4-methyl­benzoate anion via N—H+⋯O and C—H⋯O hydrogen bonds, forming a tape-like supra­molecular structure.

Keywords: crystal structure, levofloxacinium 4-methyl­benzoate salt, Hirshfeld, X-ray diffraction, hydrogen-bonding inter­actions

Abstract

The anhydrous salt levofloxacinium 4-methyl­benzoate, C18H21FN3O4+·C8H7O2, has been synthesized and its crystal structure determined. In the crystal, the levofloxacinium ions inter­act with the 4-methyl­benzoate anion via N—H+⋯O and C—H⋯O hydrogen bonds, forming a tape-like supra­molecular structure. Hirshfeld surface analysis and the calculated two-dimensional finger plots of the various atom–atom contacts involving both the ions are described.

1. Chemical context

Small organic mol­ecules and peptides have been known for decades for their aesthetic supra­molecular architectures (Prabhakaran et al., 2009; Upadhye et al., 2009) and various applications including in the pharmaceutical industry (Shah et al., 2023; Karmakar et al., 2025; Gellman, 1998). Fluoro­quinolones belonging to a class of broad-spectrum anti­biotics having advantageous pharmacokinetic properties and are used in the treatment of various bacterial infections. Levofloxacin, (levo isomer of oflaxacin), systematic name: S-(−)-9-fluoro-2,3-di­hydro-3-methyl-10-(4-methyl-1-piperazin­yl)-7-oxo-7H-pyri­dine­[1,2,3-de]-1,4-benzoxazine-6-carb­oxy­lic acid, C18H20FN3O4, is a fluorinated third-generation fluoro­quinolone anti­biotic employed in the treatment of respiratory, urinary tract, cutaneous allergy and various other infections caused by Gram-positive and Gram-negative bacteria. A therapeutic review discussing the pharmacology, pharmacokinetics, in vitro activity, drug inter­actions, and adverse effects of levofloxacin has been published (Wimer et al., 1998) and the use of levofloxacin in the treatment of community-acquired pneumonia was described (Noreddin et al., 2010). A cohort analysis describing levofloxacin dosage to treat bone and joint infections was reported (Asseray et al., 2016). A literature review of the levofloxacin in veterinary medicine was published recently wherein levofloxacin MIC values of animal microbial isolates are summarized (Sitovs et al., 2021). A review on data summarizing the efficacy and the tolerability of levofloxacin in treating complicated urinary tract infections (UTIs) and pyelonephritis was described (Bientinesi et al., 2020), as well as a review of levofloxacin for the treatment of bacterial infections (Noel, 2009) has also been published. Recently, a retrospective observational study of the efficacy and safety of levofloxacin in children with severe infections was conducted (Junqi et al., 2024). Recently, levofloxacinium citrate salt hydrate (Nugrahani et al., 2024) was reported, the crystal structure of which features O—H⋯O, N—H⋯O and C—H⋯O inter­actions. Various solvates of levofloxacin and its citrate salt have also been reported (Nugrahani et al., 2022) wherein improvement in the anti­biotic potency and an anti­biotic–anti­oxidant combination for drug dosage development was reported. A study involving salts of levofloxacin with 2,6- and 3,5-di­hydroxy­benzoic acid showed increased stability and anti­biotic potency improvement (Nugrahani et al., 2023). More recently, a drug–drug salt of levofloxacin flufenamic acid was reported along with its physicochemical properties, potency and anti-inflammation improvements that could be developed further into dosage formulations (Nugrahani et al., 2025).

The preparation of anhydrous forms of levofloxacin, salts or co-crystals (Freitas et al., 2018; Wei et al., 2019) continues to be challenging as these anhydrous forms readily convert into hemihydrate/hydrate forms (Singh et al., 2014). Continuing our research in the area of co-crystals (e.g. PrakashaReddy et al., 2004), we herein report the synthesis of a new anhydrous levofloxacinium:4-methyl­benzoate salt, (I). We have determined its mol­ecular and crystal structures and conducted a Hirshfeld surface analysis to examine the inter­molecular inter­actions.1.

2. Structural commentary

Reaction between levofloxacin and 4-methyl­benzoic acid yielded the title salt, (I), which crystallizes in the ortho­rhom­bic P212121 space group with one ion pair in the asymmetric unit. The mol­ecular structure of the salt along with the atom-labelling is shown in Fig. 1. The quinoline ring along with the other attached carboxyl and fluorine atoms in the levofloxacinium are essentially planar (r.m.s. deviation = 0.0659 Å), as observed in another salt hydrate reported in the literature (Golovnev et al., 2018). On the other hand, the carboxyl­ate group in the 4-methyl­benzoate is twisted notably from the planarity of methyl aromatic plane with a torsion angle of −18.1 (8)o for the chain of O5—C21—C22—C27 atoms. An intra­molecular O2—H2⋯O3 hydrogen bond is observed between the hy­droxy O atom of the –COOH group and the adjacent quinoline oxygen atom, forming an S(6) ring motif, as seen in other salts/co-crystals of levofloxacin reported in the literature (Nugrahani et al., 2022).

Figure 1.

Figure 1

The mol­ecular structure of the levofloxacinium:4-methyl­benzoate salt, showing the atom labelling and displacement ellipsoids drawn at the 30% probability level. Intra­molecular hydrogen bonds are drawn as thick dashed lines while inter­molecular hydrogen bonds are drawn as thin dashed lines.

3. Supra­molecular features

In the crystal, inter­molecular hydrogen-bonding inter­actions are observed. Levofloxacinium and 4-methyl­benzoate ions are connected through the N5—H6⋯O8 inter­action (Table 1). Further, a hydrogen atom of the methyl group of 4-methyl­benzoate inter­acts with the hy­droxy group –COOH of the levofloxacinium cation through the C28—H28B⋯O2 hydrogen bond (Desiraju, et al., 1999; Patel, et al., 2024), forming a tape-like supra­molecular structure as shown in Fig. 2. In addition, a number of other C—H⋯O inter­actions (C16—H16B⋯O2, C12—H12C⋯O3, C11—H11⋯O6, C15—H15B⋯O1, C10—H10⋯O6, C13—H13A⋯O3) between levofloxacinium ions and both levofloxacinium and 4-methyl­benzoate are observed in the crystal structure as shown in Fig. 3. The three-dimensional projection along the crystallographic b-axis is shown in Fig. 4.

Table 1. Hydrogen-bond geometry (Å, °).

D—H⋯A D—H H⋯A DA D—H⋯A
O2—H2⋯O3 0.82 1.76 2.522 (6) 155
N3—H3⋯O5 0.98 1.63 2.610 (6) 175
N3—H3⋯O6 0.98 2.51 3.125 (6) 121
C11—H11⋯O6i 0.98 2.28 3.147 (6) 147
C12—H12C⋯O3ii 0.96 2.52 3.308 (8) 139
C13—H13A⋯O3iii 0.97 2.40 3.302 (8) 154
C14—H14B⋯F1 0.97 2.30 2.785 (6) 110
C15—H15B⋯O1iv 0.97 2.58 3.268 (7) 128
C16—H16B⋯O2ii 0.97 2.55 3.277 (7) 131
C18—H18C⋯F1v 0.96 2.54 3.279 (8) 134
C28—H28B⋯O2vi 0.96 2.60 3.481 (7) 153

Symmetry codes: (i) Inline graphic; (ii) Inline graphic; (iii) Inline graphic; (iv) Inline graphic; (v) Inline graphic; (vi) Inline graphic.

Figure 2.

Figure 2

Formation of supra­molecular tape-like structure through N—H+⋯O and C—H⋯O inter­actions in the crystal.

Figure 3.

Figure 3

Various other C—H⋯O inter­actions observed in the crystal.

Figure 4.

Figure 4

Three-dimensional packing viewed along the b-axis direction.

4. Hirshfeld surfaces and 2D fingerprint plots

A Hirshfeld surface analysis and corresponding fingerprint plots were generated using CrystalExplorer software (Spackman et al., 2021; Spackman & Jayatilaka, 2009) to further investigate and determine the contributions of the several inter­molecular inter­actions in the crystal. The Hirshfeld surface mapped over dnorm with the corresponding two-dimensional fingerprint plots (McKinnon et al., 2007) for all inter­molecular inter­actions and those delineated into specific contacts are shown in Fig. 5. The largest contribution comes from H⋯H contacts at 48.6% of the total, which is consistent with the significant hydrogen content of the mol­ecule. The next most important contact is O⋯H/H⋯O at 24.5%, which primarily comes from the intra­molecular O—H⋯O and inter­molecular N—H⋯O as well as C—H⋯O inter­actions. The C⋯H/H⋯C inter­actions account for 12.1% while C⋯C contacts contribute 6.6%, followed by F⋯H/H⋯F contacts contributing 4.6%.

Figure 5.

Figure 5

Hirshfeld surfaces of title compound mapped with dnorm (left image of each pair) and the corresponding two-dimensional fingerprint plots (right image of each pair) showing all contributions and then the major contributions of H⋯H followed by O⋯H/H⋯O, C⋯H/H⋯C, C⋯C and F⋯H/H⋯F contacts.

5. Synthesis and crystallization

Levofloxacin and 4-methyl­benzoic acid were obtained from Aldrich, and HPLC grade methanol was used for reaction. Levofloxacin (100 mg, 0.277 mmol) was dissolved in methanol (10 ml) under constant stirring at 335 K for 40 min. Equimolar solution of 4-methyl­benzoic acid (38 mg, 0.277 mmol) in methanol (10 ml) was added to the solution of levofloxacin and stirring was continued further for about 30 min at 335 K. The mixture was cooled to room temperature and the solution was filtered. X-ray quality single crystals of suitable dimension were obtained over a period of ten days by slow evaporation of the solvent.

6. Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2. All hydrogen atoms were placed at idealized positions and refined using a riding model. The assignment of the absolute configuration is based on levofloxacin.

Table 2. Experimental details.

Crystal data
Chemical formula C18H21FN3O4+·C8H7O2
M r 497.51
Crystal system, space group Orthorhombic, P212121
Temperature (K) 120
a, b, c (Å) 7.1788 (10), 13.0274 (13), 25.979 (3)
V3) 2429.6 (5)
Z 4
Radiation type Mo Kα
μ (mm−1) 0.10
Crystal size (mm) 0.39 × 0.29 × 0.23
 
Data collection
Diffractometer Bruker SMART APEXII CCD
Absorption correction Analytical (SADABS; Krause et al., 2015)
Tmin, Tmax 0.575, 0.746
No. of measured, independent and observed [I > 2σ(I)] reflections 17036, 5409, 2456
R int 0.116
(sin θ/λ)max−1) 0.644
 
Refinement
R[F2 > 2σ(F2)], wR(F2), S 0.060, 0.177, 1.00
No. of reflections 5409
No. of parameters 330
H-atom treatment H-atom parameters constrained
Δρmax, Δρmin (e Å−3) 0.23, −0.17
Absolute structure Flack x determined using 707 quotients [(I+)−(I)]/[(I+)+(I)] (Parsons et al., 2013)
Absolute structure parameter 0.02 (10)

Computer programs: APEX2 (Bruker, 2005), SAINT (Bruker, 2017), SHELXT2018/2 (Sheldrick, 2015a), SHELXL2019/3 (Sheldrick, 2015b) and OLEX2 (Dolomanov et al., 2009).

Supplementary Material

Crystal structure: contains datablock(s) I. DOI: 10.1107/S2056989025010047/ee2021sup1.cif

e-81-01149-sup1.cif (517.4KB, cif)

Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989025010047/ee2021Isup2.hkl

e-81-01149-Isup2.hkl (430.4KB, hkl)
e-81-01149-Isup3.cml (9.9KB, cml)

Supporting information file. DOI: 10.1107/S2056989025010047/ee2021Isup3.cml

CCDC reference: 2502089

Additional supporting information: crystallographic information; 3D view; checkCIF report

Acknowledgments

The authors are grateful to the Indrashil University and Central University of Gujarat, India, for research facilities. One of the authors (BCP) is indebted to the Knowledge Consortium of Gujarat (KCG), Department of Education, Government of Gujarat, India for a SHODH-Scheme fellowship. We thank an anonymous referee for constructive comments and suggestions.

supplementary crystallographic information

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Crystal data

C18H21FN3O4+·C8H7O2 Dx = 1.360 Mg m3
Mr = 497.51 Mo Kα radiation, λ = 0.71073 Å
Orthorhombic, P212121 Cell parameters from 3952 reflections
a = 7.1788 (10) Å θ = 2.5–27.5°
b = 13.0274 (13) Å µ = 0.10 mm1
c = 25.979 (3) Å T = 120 K
V = 2429.6 (5) Å3 Irregular, clear whiteish colourless
Z = 4 0.39 × 0.29 × 0.23 mm
F(000) = 1048

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Data collection

Bruker SMART APEXII CCD diffractometer 2456 reflections with I > 2σ(I)
Radiation source: fine-focus sealed xray tube Rint = 0.116
ω scans θmax = 27.2°, θmin = 1.8°
Absorption correction: analytical (SADABS; Krause et al., 2015) h = −9→9
Tmin = 0.575, Tmax = 0.746 k = −16→14
17036 measured reflections l = −33→33
5409 independent reflections

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Refinement

Refinement on F2 Hydrogen site location: inferred from neighbouring sites
Least-squares matrix: full H-atom parameters constrained
R[F2 > 2σ(F2)] = 0.060 w = 1/[σ2(Fo2) + (0.0526P)2] where P = (Fo2 + 2Fc2)/3
wR(F2) = 0.177 (Δ/σ)max = 0.001
S = 1.00 Δρmax = 0.23 e Å3
5409 reflections Δρmin = −0.17 e Å3
330 parameters Absolute structure: Flack x determined using 707 quotients [(I+)-(I-)]/[(I+)+(I-)] (Parsons et al., 2013)
0 restraints Absolute structure parameter: 0.02 (10)
Primary atom site location: dual

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Special details

Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)

x y z Uiso*/Ueq
F1 0.3846 (6) 0.4254 (2) 0.48601 (11) 0.0839 (13)
O4 0.4409 (7) 0.6279 (2) 0.63599 (12) 0.0654 (13)
O3 0.4055 (6) 0.7860 (3) 0.41864 (13) 0.0690 (12)
N1 0.4331 (7) 0.8049 (3) 0.57537 (14) 0.0507 (12)
O5 0.5049 (7) 0.1973 (2) 0.69163 (16) 0.0809 (14)
O2 0.4106 (8) 0.9794 (3) 0.41499 (15) 0.0817 (14)
H2 0.412608 0.918689 0.406726 0.123*
O6 0.5051 (8) 0.0488 (3) 0.65068 (18) 0.1007 (18)
N3 0.2677 (7) 0.2393 (3) 0.61849 (16) 0.0592 (14)
H3 0.351504 0.221625 0.646927 0.071*
N2 0.4162 (8) 0.4350 (3) 0.59214 (17) 0.0709 (16)
O1 0.4224 (8) 1.0696 (3) 0.48648 (15) 0.0909 (17)
C3 0.4150 (8) 0.7922 (4) 0.46730 (19) 0.0529 (14)
C2 0.4216 (8) 0.8873 (3) 0.49351 (19) 0.0510 (14)
C4 0.4170 (8) 0.7005 (3) 0.49911 (19) 0.0482 (13)
C7 0.4161 (9) 0.5228 (3) 0.5618 (2) 0.0530 (15)
C9 0.4225 (8) 0.7085 (3) 0.55283 (17) 0.0469 (13)
C8 0.4276 (8) 0.6204 (3) 0.58383 (17) 0.0505 (14)
C10 0.4327 (8) 0.8895 (4) 0.54619 (19) 0.0546 (15)
H10 0.440276 0.952924 0.562442 0.066*
C11 0.4308 (10) 0.8137 (3) 0.63186 (17) 0.0558 (16)
H11 0.502388 0.874645 0.641728 0.067*
C6 0.4047 (9) 0.5197 (4) 0.5082 (2) 0.0577 (16)
C16 0.1705 (9) 0.3364 (3) 0.6321 (2) 0.0596 (16)
H16A 0.101626 0.326800 0.663871 0.072*
H16B 0.082101 0.353582 0.605224 0.072*
C22 0.7367 (9) 0.0768 (4) 0.71312 (19) 0.0565 (16)
C5 0.4083 (9) 0.6029 (4) 0.4772 (2) 0.0574 (16)
H5 0.405122 0.595200 0.441643 0.069*
C1 0.4181 (10) 0.9871 (4) 0.4657 (2) 0.0651 (18)
C25 1.0649 (9) 0.0146 (4) 0.7643 (2) 0.0609 (16)
C23 0.7906 (10) −0.0257 (4) 0.7157 (2) 0.0700 (19)
H23 0.717649 −0.075398 0.699742 0.084*
C21 0.5685 (10) 0.1086 (4) 0.6829 (2) 0.0678 (18)
C17 0.3068 (10) 0.4240 (4) 0.63871 (19) 0.0628 (17)
H17A 0.239637 0.487146 0.645588 0.075*
H17B 0.388308 0.410274 0.667678 0.075*
C13 0.5267 (10) 0.7203 (3) 0.65338 (19) 0.0639 (17)
H13A 0.656407 0.720735 0.642957 0.077*
H13B 0.522493 0.722761 0.690684 0.077*
C24 0.9502 (10) −0.0553 (4) 0.7415 (2) 0.0657 (18)
H24 0.980162 −0.124614 0.743378 0.079*
C15 0.3828 (10) 0.2534 (4) 0.5714 (2) 0.073 (2)
H15A 0.302064 0.266210 0.542151 0.088*
H15B 0.452586 0.191077 0.564583 0.088*
C27 0.8484 (11) 0.1468 (4) 0.7376 (2) 0.074 (2)
H27 0.815831 0.215889 0.737288 0.089*
C26 1.0093 (12) 0.1159 (4) 0.7628 (2) 0.085 (2)
H26 1.081991 0.165116 0.779177 0.102*
C14 0.5154 (10) 0.3417 (4) 0.5778 (2) 0.076 (2)
H14A 0.606069 0.325097 0.604224 0.091*
H14B 0.581967 0.352980 0.545812 0.091*
C12 0.2334 (11) 0.8264 (4) 0.6508 (2) 0.080 (2)
H12A 0.178361 0.885510 0.634783 0.120*
H12B 0.233870 0.835415 0.687461 0.120*
H12C 0.162330 0.766401 0.642152 0.120*
C28 1.2434 (10) −0.0176 (5) 0.7894 (2) 0.083 (2)
H28A 1.255020 −0.090935 0.787757 0.125*
H28B 1.243211 0.003861 0.824784 0.125*
H28C 1.346502 0.013623 0.771844 0.125*
C18 0.1332 (11) 0.1541 (4) 0.6121 (3) 0.086 (2)
H18A 0.071686 0.141200 0.644297 0.129*
H18B 0.198158 0.093334 0.601357 0.129*
H18C 0.042429 0.172378 0.586578 0.129*

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Atomic displacement parameters (Å2)

U11 U22 U33 U12 U13 U23
F1 0.124 (4) 0.0551 (17) 0.072 (2) −0.009 (2) 0.020 (2) −0.0210 (15)
O4 0.098 (4) 0.0453 (17) 0.053 (2) 0.002 (2) −0.007 (2) −0.0014 (15)
O3 0.079 (3) 0.079 (2) 0.048 (2) −0.001 (3) 0.003 (2) 0.0036 (18)
N1 0.060 (4) 0.044 (2) 0.049 (2) 0.000 (2) −0.004 (2) −0.0011 (17)
O5 0.096 (4) 0.050 (2) 0.097 (3) 0.015 (2) −0.025 (3) −0.0044 (19)
O2 0.102 (4) 0.077 (2) 0.066 (3) −0.015 (3) −0.006 (3) 0.020 (2)
O6 0.119 (5) 0.057 (2) 0.127 (4) 0.012 (2) −0.065 (4) −0.019 (2)
N3 0.068 (4) 0.044 (2) 0.066 (3) 0.001 (2) −0.011 (3) −0.0008 (19)
N2 0.097 (5) 0.042 (2) 0.074 (3) 0.013 (3) 0.031 (3) 0.005 (2)
O1 0.138 (5) 0.052 (2) 0.083 (3) 0.000 (3) −0.006 (3) 0.009 (2)
C3 0.039 (4) 0.065 (3) 0.055 (3) 0.001 (3) −0.001 (3) 0.003 (2)
C2 0.044 (4) 0.049 (3) 0.060 (3) 0.001 (3) −0.003 (3) 0.004 (2)
C4 0.041 (4) 0.050 (3) 0.054 (3) 0.000 (3) 0.001 (3) −0.002 (2)
C7 0.058 (4) 0.041 (2) 0.060 (3) 0.004 (3) 0.008 (3) 0.000 (2)
C9 0.050 (4) 0.043 (2) 0.048 (3) 0.002 (3) −0.002 (3) −0.002 (2)
C8 0.056 (4) 0.048 (2) 0.047 (3) 0.006 (3) 0.003 (3) −0.001 (2)
C10 0.052 (4) 0.046 (3) 0.065 (3) 0.003 (3) −0.008 (3) 0.002 (2)
C11 0.074 (5) 0.048 (3) 0.045 (3) −0.003 (3) −0.005 (3) −0.006 (2)
C6 0.065 (5) 0.049 (3) 0.060 (4) −0.001 (3) 0.008 (3) −0.014 (3)
C16 0.064 (5) 0.049 (3) 0.066 (3) 0.010 (3) −0.001 (3) 0.001 (3)
C22 0.064 (5) 0.047 (3) 0.058 (3) 0.001 (3) −0.011 (3) 0.000 (2)
C5 0.060 (5) 0.059 (3) 0.053 (3) 0.002 (3) 0.003 (3) −0.008 (2)
C1 0.066 (5) 0.063 (3) 0.066 (4) −0.002 (4) −0.006 (4) 0.015 (3)
C25 0.059 (5) 0.070 (3) 0.054 (3) 0.003 (3) −0.007 (3) −0.004 (3)
C23 0.082 (6) 0.048 (3) 0.080 (4) 0.000 (3) −0.029 (4) −0.007 (3)
C21 0.079 (6) 0.051 (3) 0.073 (4) −0.008 (4) −0.012 (4) 0.000 (3)
C17 0.084 (5) 0.047 (3) 0.057 (3) 0.005 (3) 0.004 (3) 0.001 (3)
C13 0.087 (5) 0.054 (3) 0.050 (3) −0.001 (3) −0.012 (3) 0.003 (2)
C24 0.078 (6) 0.055 (3) 0.064 (3) 0.006 (3) −0.002 (4) −0.004 (3)
C15 0.093 (6) 0.052 (3) 0.076 (4) 0.009 (3) 0.010 (4) −0.008 (3)
C27 0.090 (6) 0.051 (3) 0.083 (4) 0.002 (4) −0.018 (4) −0.010 (3)
C26 0.091 (6) 0.063 (3) 0.102 (5) −0.004 (4) −0.029 (5) −0.015 (3)
C14 0.091 (6) 0.045 (3) 0.092 (4) 0.010 (3) 0.025 (4) −0.002 (3)
C12 0.100 (7) 0.081 (4) 0.060 (4) 0.014 (4) 0.011 (4) −0.004 (3)
C28 0.069 (6) 0.097 (4) 0.083 (4) 0.009 (4) −0.019 (4) −0.011 (3)
C18 0.089 (6) 0.063 (3) 0.108 (5) −0.015 (4) −0.019 (4) −0.010 (3)

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Geometric parameters (Å, º)

F1—C6 1.365 (5) C16—H16B 0.9700
O4—C8 1.362 (5) C16—C17 1.512 (8)
O4—C13 1.426 (6) C22—C23 1.392 (7)
O3—C3 1.269 (6) C22—C21 1.498 (8)
N1—C9 1.388 (6) C22—C27 1.371 (8)
N1—C10 1.337 (6) C5—H5 0.9300
N1—C11 1.472 (6) C25—C24 1.363 (7)
O5—C21 1.264 (6) C25—C26 1.379 (8)
O2—H2 0.8200 C25—C28 1.498 (8)
O2—C1 1.323 (6) C23—H23 0.9300
O6—C21 1.231 (6) C23—C24 1.382 (9)
N3—H3 0.9800 C17—H17A 0.9700
N3—C16 1.488 (6) C17—H17B 0.9700
N3—C15 1.488 (7) C13—H13A 0.9700
N3—C18 1.481 (7) C13—H13B 0.9700
N2—C7 1.389 (6) C24—H24 0.9300
N2—C17 1.449 (7) C15—H15A 0.9700
N2—C14 1.458 (6) C15—H15B 0.9700
O1—C1 1.202 (6) C15—C14 1.503 (8)
C3—C2 1.415 (6) C27—H27 0.9300
C3—C4 1.453 (6) C27—C26 1.387 (9)
C2—C10 1.371 (6) C26—H26 0.9300
C2—C1 1.487 (7) C14—H14A 0.9700
C4—C9 1.400 (7) C14—H14B 0.9700
C4—C5 1.394 (6) C12—H12A 0.9600
C7—C8 1.396 (6) C12—H12B 0.9600
C7—C6 1.396 (7) C12—H12C 0.9600
C9—C8 1.402 (6) C28—H28A 0.9600
C10—H10 0.9300 C28—H28B 0.9600
C11—H11 0.9800 C28—H28C 0.9600
C11—C13 1.505 (7) C18—H18A 0.9600
C11—C12 1.509 (9) C18—H18B 0.9600
C6—C5 1.350 (7) C18—H18C 0.9600
C16—H16A 0.9700
C8—O4—C13 114.0 (4) C24—C25—C28 121.2 (5)
C9—N1—C11 119.3 (4) C26—C25—C28 121.9 (6)
C10—N1—C9 120.4 (4) C22—C23—H23 119.3
C10—N1—C11 120.1 (4) C24—C23—C22 121.4 (5)
C1—O2—H2 109.5 C24—C23—H23 119.3
C16—N3—H3 108.0 O5—C21—C22 116.8 (5)
C15—N3—H3 108.0 O6—C21—O5 124.5 (6)
C15—N3—C16 110.6 (4) O6—C21—C22 118.7 (5)
C18—N3—H3 108.0 N2—C17—C16 109.3 (4)
C18—N3—C16 111.0 (5) N2—C17—H17A 109.8
C18—N3—C15 111.3 (4) N2—C17—H17B 109.8
C7—N2—C17 123.7 (4) C16—C17—H17A 109.8
C7—N2—C14 122.8 (4) C16—C17—H17B 109.8
C17—N2—C14 113.3 (4) H17A—C17—H17B 108.3
O3—C3—C2 122.5 (4) O4—C13—C11 111.5 (4)
O3—C3—C4 121.0 (4) O4—C13—H13A 109.3
C2—C3—C4 116.5 (4) O4—C13—H13B 109.3
C3—C2—C1 122.1 (5) C11—C13—H13A 109.3
C10—C2—C3 120.0 (4) C11—C13—H13B 109.3
C10—C2—C1 117.9 (4) H13A—C13—H13B 108.0
C9—C4—C3 120.4 (4) C25—C24—C23 121.7 (5)
C5—C4—C3 121.2 (5) C25—C24—H24 119.1
C5—C4—C9 118.4 (4) C23—C24—H24 119.1
N2—C7—C8 121.1 (4) N3—C15—H15A 109.5
N2—C7—C6 122.9 (4) N3—C15—H15B 109.5
C6—C7—C8 116.0 (4) N3—C15—C14 110.8 (4)
N1—C9—C4 119.3 (4) H15A—C15—H15B 108.1
N1—C9—C8 119.8 (4) C14—C15—H15A 109.5
C4—C9—C8 120.8 (4) C14—C15—H15B 109.5
O4—C8—C7 118.5 (4) C22—C27—H27 119.6
O4—C8—C9 121.0 (4) C22—C27—C26 120.8 (5)
C7—C8—C9 120.5 (4) C26—C27—H27 119.6
N1—C10—C2 123.3 (4) C25—C26—C27 122.2 (6)
N1—C10—H10 118.3 C25—C26—H26 118.9
C2—C10—H10 118.3 C27—C26—H26 118.9
N1—C11—H11 108.5 N2—C14—C15 110.9 (5)
N1—C11—C13 107.6 (4) N2—C14—H14A 109.5
N1—C11—C12 110.1 (5) N2—C14—H14B 109.5
C13—C11—H11 108.5 C15—C14—H14A 109.5
C13—C11—C12 113.4 (5) C15—C14—H14B 109.5
C12—C11—H11 108.5 H14A—C14—H14B 108.0
F1—C6—C7 116.9 (4) C11—C12—H12A 109.5
C5—C6—F1 118.3 (4) C11—C12—H12B 109.5
C5—C6—C7 124.8 (4) C11—C12—H12C 109.5
N3—C16—H16A 109.3 H12A—C12—H12B 109.5
N3—C16—H16B 109.3 H12A—C12—H12C 109.5
N3—C16—C17 111.4 (5) H12B—C12—H12C 109.5
H16A—C16—H16B 108.0 C25—C28—H28A 109.5
C17—C16—H16A 109.3 C25—C28—H28B 109.5
C17—C16—H16B 109.3 C25—C28—H28C 109.5
C23—C22—C21 121.0 (5) H28A—C28—H28B 109.5
C27—C22—C23 117.0 (6) H28A—C28—H28C 109.5
C27—C22—C21 122.0 (5) H28B—C28—H28C 109.5
C4—C5—H5 120.3 N3—C18—H18A 109.5
C6—C5—C4 119.3 (5) N3—C18—H18B 109.5
C6—C5—H5 120.3 N3—C18—H18C 109.5
O2—C1—C2 114.7 (5) H18A—C18—H18B 109.5
O1—C1—O2 121.0 (5) H18A—C18—H18C 109.5
O1—C1—C2 124.3 (5) H18B—C18—H18C 109.5
C24—C25—C26 116.8 (6)
F1—C6—C5—C4 176.0 (5) C10—N1—C11—C12 84.3 (6)
O3—C3—C2—C10 −179.7 (6) C10—C2—C1—O2 178.9 (6)
O3—C3—C2—C1 0.0 (10) C10—C2—C1—O1 −0.8 (10)
O3—C3—C4—C9 −178.3 (6) C11—N1—C9—C4 177.4 (5)
O3—C3—C4—C5 −0.1 (9) C11—N1—C9—C8 −6.0 (9)
N1—C9—C8—O4 0.7 (9) C11—N1—C10—C2 −175.3 (6)
N1—C9—C8—C7 179.7 (6) C6—C7—C8—O4 −179.4 (5)
N1—C11—C13—O4 −56.6 (6) C6—C7—C8—C9 1.6 (9)
N3—C16—C17—N2 56.2 (6) C16—N3—C15—C14 54.8 (6)
N3—C15—C14—N2 −54.6 (6) C22—C23—C24—C25 −1.9 (10)
N2—C7—C8—O4 0.7 (9) C22—C27—C26—C25 0.3 (10)
N2—C7—C8—C9 −178.3 (6) C5—C4—C9—N1 179.4 (5)
N2—C7—C6—F1 2.9 (10) C5—C4—C9—C8 2.8 (9)
N2—C7—C6—C5 −178.5 (6) C1—C2—C10—N1 178.6 (6)
C3—C2—C10—N1 −1.7 (10) C23—C22—C21—O5 164.6 (6)
C3—C2—C1—O2 −0.8 (9) C23—C22—C21—O6 −17.5 (9)
C3—C2—C1—O1 179.6 (7) C23—C22—C27—C26 1.2 (9)
C3—C4—C9—N1 −2.4 (9) C21—C22—C23—C24 177.0 (6)
C3—C4—C9—C8 −179.0 (5) C21—C22—C27—C26 −176.2 (6)
C3—C4—C5—C6 −177.9 (6) C17—N2—C7—C8 44.6 (9)
C2—C3—C4—C9 0.9 (9) C17—N2—C7—C6 −135.3 (6)
C2—C3—C4—C5 179.1 (6) C17—N2—C14—C15 57.0 (7)
C4—C3—C2—C10 1.1 (9) C13—O4—C8—C7 155.4 (5)
C4—C3—C2—C1 −179.2 (6) C13—O4—C8—C9 −25.6 (8)
C4—C9—C8—O4 177.2 (5) C24—C25—C26—C27 −2.5 (10)
C4—C9—C8—C7 −3.8 (9) C15—N3—C16—C17 −56.0 (6)
C7—N2—C17—C16 118.4 (6) C27—C22—C23—C24 −0.4 (9)
C7—N2—C14—C15 −118.4 (6) C27—C22—C21—O5 −18.1 (8)
C7—C6—C5—C4 −2.6 (10) C27—C22—C21—O6 159.9 (6)
C9—N1—C10—C2 0.2 (9) C26—C25—C24—C23 3.3 (9)
C9—N1—C11—C13 32.8 (8) C14—N2—C7—C8 −140.5 (6)
C9—N1—C11—C12 −91.2 (6) C14—N2—C7—C6 39.6 (10)
C9—C4—C5—C6 0.3 (9) C14—N2—C17—C16 −57.0 (7)
C8—O4—C13—C11 54.5 (6) C12—C11—C13—O4 65.4 (6)
C8—C7—C6—F1 −177.0 (5) C28—C25—C24—C23 −176.2 (6)
C8—C7—C6—C5 1.6 (10) C28—C25—C26—C27 177.0 (6)
C10—N1—C9—C4 1.9 (9) C18—N3—C16—C17 180.0 (4)
C10—N1—C9—C8 178.5 (5) C18—N3—C15—C14 178.6 (5)
C10—N1—C11—C13 −151.6 (5)

4-{11-Carboxy-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0{5,13}]trideca-5,7,9(13),11-tetraen-6-yl}-1-methylpiperazin-1-ium 4-methylbenzoate . Hydrogen-bond geometry (Å, º)

D—H···A D—H H···A D···A D—H···A
O2—H2···O3 0.82 1.76 2.522 (6) 155
N3—H3···O5 0.98 1.63 2.610 (6) 175
N3—H3···O6 0.98 2.51 3.125 (6) 121
C11—H11···O6i 0.98 2.28 3.147 (6) 147
C12—H12C···O3ii 0.96 2.52 3.308 (8) 139
C13—H13A···O3iii 0.97 2.40 3.302 (8) 154
C14—H14B···F1 0.97 2.30 2.785 (6) 110
C15—H15B···O1iv 0.97 2.58 3.268 (7) 128
C16—H16B···O2ii 0.97 2.55 3.277 (7) 131
C18—H18C···F1v 0.96 2.54 3.279 (8) 134
C28—H28B···O2vi 0.96 2.60 3.481 (7) 153

Symmetry codes: (i) x, y+1, z; (ii) x−1/2, −y+3/2, −z+1; (iii) x+1/2, −y+3/2, −z+1; (iv) x, y−1, z; (v) x−1/2, −y+1/2, −z+1; (vi) −x+3/2, −y+1, z+1/2.

References

  1. Asseray, N., Bourigault, C., Boutoille, D., Happi, L., Touchais, S., Corvec, S., Bemer, P. & Navas, D. (2016). Int. J. Antimicrob. Agents47, 478–481. [DOI] [PubMed]
  2. Bientinesi, R., Murri, R. & Sacco, E. (2020). Expert Opin. Pharmacother.21, 637–644. [DOI] [PubMed]
  3. Bruker (2005). APEX2. Bruker AXS Inc., Madison, Wisconsin, USA.
  4. Bruker (2017). SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
  5. Desiraju, G. R. & Steiner, T. (1999). The Weak Hydrogen Bond in Structural Chemistry and Biology. New York: Oxford University Press Inc.
  6. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst.42, 339–341.
  7. Freitas, J. T. J., de Melo, C. C., Viana, O. M. M. S., Ferreira, F. F. & Doriguetto, A. C. (2018). Cryst. Growth Des.18, 3558–3568.
  8. Gellman, S. H. (1998). Acc. Chem. Res.31, 173–180.
  9. Golovnev, N. N., Molokeev, M. S. & Lesnikov, M. K. (2018). J. Struct. Chem.59, 646–651.
  10. Junqi, Z., Jie, C., Jinglin, W., Jinmiao, L., Guoping, L., Yi, W. & Zhiping, L. (2024). Front. Pediatr.12, 1381742. [DOI] [PMC free article] [PubMed]
  11. Karmakar, S., Mallik, M., Sulava, S., Modi, U., Allu, S., Sangwan, S., Tothadi, S., Prakasha Reddy, J., Vasita, R., Nangia, A. K., Alone, D. P. & Prabhakaran, P. (2025). Biomater. Sci.13, 3828–3839. [DOI] [PubMed]
  12. Krause, L., Herbst-Irmer, R., Sheldrick, G. M. & Stalke, D. (2015). J. Appl. Cryst.48, 3–10. [DOI] [PMC free article] [PubMed]
  13. McKinnon, J. J., Jayatilaka, D. & Spackman, M. A. (2007). Chem. Commun. pp. 3814. [DOI] [PubMed]
  14. Noel, G. J. (2009). Clin. Med.: Ther. , 1, 433–458.
  15. Noreddin, A. M. & Elkhatib, W. F. (2010). Expert Rev. Anti Infect. Ther.8, 505–514. [DOI] [PubMed]
  16. Nugrahani, I., Laksana, A. N., Uekusa, H. & Oyama, H. (2022). Molecules27, 2166. [DOI] [PMC free article] [PubMed]
  17. Nugrahani, I., Sulaiman, M. R., Eda, C., Uekusa, H. & Ibrahim, S. (2023). Pharmaceutics15, 124. [DOI] [PMC free article] [PubMed]
  18. Nugrahani, I., Uekusa, H., Oyama, H. & Laksana, A. N. (2024). Heliyon10, e33280. [DOI] [PMC free article] [PubMed]
  19. Nugrahani, I., Uekusa, H., Wu, Y., Hori, T., Auliaurridho, H., Herawati, D., Panjaitan, F. E., Garmana, A. & Wibowo, M. S. (2025). J. Pharm. Sci.114, 103779. [DOI] [PubMed]
  20. Parsons, S., Flack, H. D. & Wagner, T. (2013). Acta Cryst. B69, 249–259. [DOI] [PMC free article] [PubMed]
  21. Patel, K., Karmakar, S., Tothadi, S., Reddy, J. P. & Prabhakaran, P. (2024). Chem. A Eur. J.30, e202303757. [DOI] [PubMed]
  22. Prabhakaran, P., Puranik, V. G., Chandran, J. N., Rajamohanan, P. R., Hofmann, H.-J. & Sanjayan, G. J. (2009). Chem. Commun. pp. 3446–3448. [DOI] [PubMed]
  23. PrakashaReddy, J. & Pedireddi, V. R. (2004). Tetrahedron60, 8817–8827.
  24. Shah, S. K. H., Modi, U., Patel, K., James, A., N, S., De, S., Vasita, R. & Prabhakaran, P. (2023). Biomater. Sci.11, 6210–6222. [DOI] [PubMed]
  25. Sheldrick, G. M. (2015a). Acta Cryst. A71, 3–8.
  26. Sheldrick, G. M. (2015b). Acta Cryst. C71, 3–8.
  27. Singh, S. S. & Thakur, T. S. (2014). CrystEngComm16, 4215–4230.
  28. Sitovs, A., Sartini, I. & Giorgi, M. (2021). Res. Vet. Sci.137, 111–126. [DOI] [PubMed]
  29. Spackman, M. A. & Jayatilaka, D. (2009). CrystEngComm11, 19–32.
  30. Spackman, P. R., Turner, M. J., McKinnon, J. J., Wolff, S. K., Grimwood, D. J., Jayatilaka, D. & Spackman, M. A. (2021). J. Appl. Cryst.54, 1006–1011. [DOI] [PMC free article] [PubMed]
  31. Upadhye, K., PrakashaReddy, J. & Pedireddi, V. R. (2009). J. Mol. Struct.937, 81–84.
  32. Wei, N., Jia, L., Shang, Z., Gong, J., Wu, S., Wang, J. & Tang, W. (2019). CrystEngComm21, 6196–6207.
  33. Wimer, S. M., Schoonover, L. & Garrison, M. W. (1998). Clin. Ther.20, 1049–1070. [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Crystal structure: contains datablock(s) I. DOI: 10.1107/S2056989025010047/ee2021sup1.cif

e-81-01149-sup1.cif (517.4KB, cif)

Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989025010047/ee2021Isup2.hkl

e-81-01149-Isup2.hkl (430.4KB, hkl)
e-81-01149-Isup3.cml (9.9KB, cml)

Supporting information file. DOI: 10.1107/S2056989025010047/ee2021Isup3.cml

CCDC reference: 2502089

Additional supporting information: crystallographic information; 3D view; checkCIF report


Articles from Acta Crystallographica Section E: Crystallographic Communications are provided here courtesy of International Union of Crystallography

RESOURCES